Immuron Limited (IMC)

Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

Sign Up Today » it's FREE! Already a member? Login now!

General Information
Company Name: Immuron Limited
Stock Code: IMC
GICS Sub-Industry: Pharmaceuticals
Market Cap ($M): 18
Equiv. Shares (M): 2,996

Current Price Data+
Current Price Open High Low Last Close Volume Price Movement
 $ 0.006 $ 0.007 $ 0.007 $ 0.006 $ 0.007 3,050,000 $ -0.001  -14.286 %

Company Overview

Business Description:
Immuron Limited (IMC) is a biopharmaceutical company focused on oral immunotherapy treatments using dairy-derived antibody products for humans. IMC’s products ranges target infectious diseases of the gastrointestinal tract, chronic diseases such as fatty liver/NASH, and influenza. IMC has one product in the market, Travelan, for preventing travellers’ diarrhoea and seven products under research and development process.

Financial Summary
Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2014  A -2.5 -0.2 -- 0.0 0.0 0.0 --
2013  A -3.5 -0.6 -- 0.0 0.0 0.0 --
2012  A -2.3 -0.4 -- 0.0 0.0 0.0 --
Source: Aspect actuals / Thomson IBES estimates

Peer Comparison
EPS Growth (%) P/E (%) Dividend Yield (%)
Company Mkt Cap 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F
Acrux Limited (ACR) $231 M 3.0384 -0.2232 1.9885 8.2738 10.6513 3.5641 14.39 6.81 7.42
Immuron (IMC) $21 M -- -- -- -- -- -- 0.00 -- --
Mayne Pharma Group (MYX) $438 M 1.0457 0.0032 0.2739 23.8019 23.7261 18.6250 0.00 0.00 0.00

Market Comparison
Earnings P/E Ratio P/B Ratio P/E Growth P/S Ratio
IMC -- -- 2.61 -- 10.00
Market 1.08 13.6 1.03 1.03 3.12
Sector 0.67 20.9 2.84 1.68 8.44

Name Position Start Date
Dr Roger Aston Non-Executive Chairman 25 May 2012
Mr Daniel Pollock Non-Executive Director 11 October 2012
Mr Stephen Anastasiou Non-Executive Director 28 May 2013

Name Position
Amos Meltzer Chief Executive Officer
Graeme Stevens Company Secretary and Chief Financial Officer
Phillip Hains Joint Company Secretary
Peter Vaughan Joint Company Secretary

Substantial Shareholders
Holding Name
59,164,094 (5.71%) Hadasit Medical Research Services & Development Ltd
168,326,929 (16.56%) Grandlodge Pty Ltd
146,576,329 (14.42%) David Plush and Texas Woods Pty Ltd
54,627,723 (5.38%) Capital Concerns Pty Limited <Logue Family Super Fund>

Calendar of Events
Date Event
28 August 2015 Report (Annual)
28 August 2015 Report (Prelim)
27 February 2015 Report (Interim)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at


Trade Shares Online from $19.95^
Free Guides

The SMH Guide to Investment Fees

An educational booklet to help you find out everything you must know about investment fees.

More details...


The Importance of Ignoring the Noise of the Market

Carl Richards, director of investor education at the BAM Alliance 17/10/2014 | “As odd as it may sound, the sooner you start treating your investments like you treat life, the happier you’ll be with the outcome.”

You only dance twice

William H. Gross, Janus Capital Group 16/10/2014 | “Financial markets are artificially priced. In the bond market, there is nothing normal about a three year German Bund yielding “minus” 10 basis points.”

The Big Picture - Australia 200 Index

CMC Markets 8/10/2014 | Share market indices around the globe are breaking down. While analysts cast around for reasons, it’s clear that a time factor is in play. Simply put, many investors “feel” a correction is overdue. How low could it go?

Billionaires bankroll Ten's new direction Media Network sees digital future

The Age 19/12/2013 | Ten Network's programming ambitions will be funded by a $200 million loan guaranteed by three of its billionaire owners, as the free-to-air broadcaster declared digital was the future and pointed to early signs that its switch to an older market demographic was working.

Elders alleges $24m fraud in live cattle division

The Age 19/12/2013 | Troubled rural services group Elders is threatening to call in the police over an alleged $24 million fraud by a "handful of individuals" in its live cattle exports division.

Bega Cheese holds back in three-way bidding war for WCB

The Age 19/12/2013 | Bega Cheese began the battle for Warrnambool Cheese & Butter but three months on it appears to be the first casualty of the bidding war.


Sponsored Links